HL-400

N/A

Report date: 2026/05/26 16:07:26
NME

Base Information

Drug NameHL-400
Drug Alias NameHL400HL-400
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Highlightll Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHighlightll Pharmaceutical (USA) LLCHangzhou Highlightll Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A